Wellness Center USA (WCUI) 10-Q 25 Aug 20 2020 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information	9 Months Ended
	Jun. 30, 2020shares
Cover [Abstract]
Entity Registrant Name	Wellness Center USA, Inc.
Entity Central Index Key	0001516887
Document Type	10-Q
Document Period End Date	Jun. 30, 2020
Amendment Flag	false
Current Fiscal Year End Date	--09-30
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business Flag	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding	116,319,577
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2020

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Jun. 30, 2020	Sep. 30, 2019
Current Assets
Cash	$ 94,318	$ 53,147
Accounts receivable	5,000
Inventories	72,075
Prepaid expenses and other current assets	500	55,000
Total Current Assets	171,893	108,147
Property and equipment, net		1,562
Right of use asset	12,257
Total Other Assets	12,257	1,562
TOTAL ASSETS	184,150	109,709
Current Liabilities
Accounts payable and accrued expenses	479,558	457,037
Payroll taxes payable	96,834	102,834
Lease liability	12,257
Lease abandonment liability	672,878	234,582
Loans payable from officers and shareholders	1,054,250	399,250
Total Current Liabilities	2,315,777	1,193,703
Long-term Liabilities
U.S. Small Business Administration PPP loan payable	37,166
Total Long-term Liabilities	37,166
Shareholders' Deficit
Common stock, par value $0.001, 200,000,000 shares authorized; 116,319,577 and 107,497,077 shares issued and outstanding, respectively	116,320	107,497
Additional paid-in capital	24,843,353	23,777,647
Accumulated deficit	(27,425,368)	(25,362,287)
Total Wellness Center USA shareholders' deficit	(2,465,695)	(1,477,143)
Non-controlling interest	296,902	393,149
Total Shareholder's deficit	(2,168,793)	(1,083,994)
TOTAL LIABILITIES AND SHAREHOLDERS' DEFICIT	$ 184,150	$ 109,709

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Jun. 30, 2020	Sep. 30, 2019
Statement of Financial Position [Abstract]
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	200,000,000	200,000,000
Common stock, shares, issued	116,319,577	107,497,077
Common stock, shares, outstanding	116,319,577	107,497,077

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Sales:
Total Sales		$ 7,625	$ 5,000	$ 33,375
Cost of goods sold		4,575		20,025
Gross profit		3,050	5,000	13,350
Operating expenses	813,380	404,210	1,573,783	1,415,667
Loss from operations	(813,380)	(401,160)	(1,568,783)	(1,402,317)
Other income (expense)
U.S. federal government COVID-19 grant	4,000		4,000
Amortization of debt discount				(72,078)
Financing costs	(43,815)	(108,630)	(43,815)	(182,064)
Cost of stock option modifications	(22,680)		22,680
Cost of stock warrant modification			(507,265)
Interest expense	(19,751)	(6,042)	(45,285)	(17,771)
Total other income (expense)	(82,246)	(114,672)	(615,045)	(271,913)
NET LOSS	(895,626)	(515,832)	(2,183,828)	(1,674,230)
Net loss attributable to non-controlling interest	76,568	4,917	120,747	9,319
Loss from deconsolidation of non-controlling interest				(405,383)
NET LOSS ATTRIBUTABLE TO WELLNESS CENTER USA, INC.	$ (819,058)	$ (510,915)	$ (2,063,081)	$ (2,070,294)
BASIC AND DILUTED LOSS PER SHARE	$ (0.01)	$ 0	$ (0.02)	$ (0.02)
WEIGHTED-AVERAGE COMMON SHARES OUTSTANDING BASIC AND DILUTED	110,909,467	107,433,349	108,634,540	106,575,313
Trade [Member]
Sales:
Total Sales		$ 3,108	$ 5,000	$ 19,508
Consulting Services [Member]
Sales:
Total Sales		$ 4,517		$ 13,867

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Shareholders' Deficit (Unaudited) - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]	Total WCUI Deficit [Member]	Non-controlling Interest [Member]	Total
Balance at Sep. 30, 2018	$ 100,952	$ 22,450,252	$ (22,974,740)	$ (423,536)	$ (401,624)	$ (825,160)
Balance, shares at Sep. 30, 2018	100,952,569
Common shares issued for cash	$ 143	9,857		10,000		10,000
Common shares issued for cash, shares	142,857
Shares issued upon conversion of note payable	$ 4,811	285,361		290,172		290,172
Shares issued upon conversion of note payable, shares	4,810,222
Fair value of common stock issued with convertible note payable	$ 314	21,686		22,000		22,000
Fair value of common stock issued with convertible note payable, shares	314,286
Fair value of additional shares issued to conversions of note payable		160,064		160,064		160,064
Fair value of vested stock options		235,819		235,819		235,819
Fair value of common stock issued for services	$ 1,277	77,752		79,029		79,029
Fair value of common stock issued for services, shares	1,277,143
Termination of non-controlling interest agreement			(405,383)	(405,383)	405,383
Contribution of capital by joint venture partner		476,000		(476,000)	224,000	700,000
Net loss			(1,664,911)	(1,664,911)	(9,319)	(1,674,230)
Balance at Jun. 30, 2019	$ 107,497	23,716,791	(25,045,034)	(1,220,746)	218,440	(1,002,306)
Balance, shares at Jun. 30, 2019	107,497,077
Balance at Mar. 31, 2019	$ 104,012	23,200,187	(24,534,119)	(1,229,920)	151,357	(1,078,563)
Balance, shares at Mar. 31, 2019	104,012,153
Fair value of common stock issued with convertible note payable	$ 2,328	114,061		116,389		116,389
Fair value of common stock issued with convertible note payable, shares	2,327,781
Fair value of additional shares issued to conversions of note payable		108,630		108,630		108,630
Fair value of vested stock options		72,641		72,641		72,641
Fair value of common stock issued for services	$ 1,157	68,272		69,429		69,429
Fair value of common stock issued for services, shares	1,157,143
Contribution of capital by joint venture partner		153,000		153,000	72,000	225,000
Net loss			(510,915)	(510,915)	(4,917)	(515,832)
Balance at Jun. 30, 2019	$ 107,497	23,716,791	(25,045,034)	(1,220,746)	218,440	(1,002,306)
Balance, shares at Jun. 30, 2019	107,497,077
Balance at Sep. 30, 2019	$ 107,497	23,777,647	(25,362,287)	(1,477,143)	393,149	(1,083,994)
Balance, shares at Sep. 30, 2019	107,497,077
Fair value of additional shares issued to conversions of note payable		43,815		43,815		43,815
Fair value of vested stock options		197,844		197,844		197,844
Fair value of common stock issued for services	$ 8,248	239,177		247,425		247,425
Fair value of common stock issued for services, shares	8,247,500
Contribution of capital by joint venture partner		25,500		25,500	24,500	50,000
Conversion of loan payable from shareholder into common shares	$ 575	29,425		30,000		30,000
Conversion of loan payable from shareholder into common shares, shares	575,000
Cost of warrant modification		507,265		507,265		507,265
Cost of stock option modifications		22,680		22,680		22,680
Net loss			(2,063,081)	(2,063,081)	(120,747)	(2,183,828)
Balance at Jun. 30, 2020	$ 116,320	24,843,353	(27,425,368)	(2,465,695)	296,902	(2,168,793)
Balance, shares at Jun. 30, 2020	116,319,577
Balance at Mar. 31, 2020	$ 107,497	24,441,950	(26,606,310)	(2,056,863)	373,470	(1,683,393)
Balance, shares at Mar. 31, 2020	107,497,077
Fair value of additional shares issued to conversions of note payable		43,815		43,815		43,815
Fair value of vested stock options		66,306		66,306		66,306
Fair value of common stock issued for services	$ 8,248	239,177		247,425		247,425
Fair value of common stock issued for services, shares	8,247,500
Conversion of loan payable from shareholder into common shares	$ 575	29,425		30,000		30,000
Conversion of loan payable from shareholder into common shares, shares	575,000
Cost of stock option modifications		22,680		22,680		22,680
Net loss			(819,058)	(819,058)	(76,568)	(895,626)
Balance at Jun. 30, 2020	$ 116,320	$ 24,843,353	$ (27,425,368)	$ (2,465,695)	$ 296,902	$ (2,168,793)
Balance, shares at Jun. 30, 2020	116,319,577

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Cash Flows from Operating Activities
Net loss	$ (2,183,828)	$ (1,674,230)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation expense	1,562	792
Amortization of right-of-use asset	15,584
Amortization of debt discount		72,078
Fair value of common shares issued for services	247,425	79,029
Fair value of stock options issued for services	197,844	235,819
Fair value of additional shares issued upon conversions of note payable		160,064
Fair value of warrants issued upon conversion of loan payable from shareholder	43,815
Loss on abandonment of lease	438,296	22,000
Loss on modification of conversion price on convertible note payable		65,000
Cost of stock option modifications	22,680
Cost of warrant modification	507,265
(Increase) Decrease in:
Accounts receivable	(5,000)
Inventories	(17,075)	(55,000)
Prepaid expenses and other assets	(500)	16,550
(Decrease) Increase in:
Accounts payable and accrued expenses	22,521	113,665
Payroll taxes payable	(6,000)
Lease liability	(15,584)
Deferred revenue		(8,624)
Net cash used in operating activities	(730,995)	(972,857)
Cash Flows from Financing Activities
Proceeds from loans payable from officers and shareholders	685,000	333,250
Repayment of loans payable from officers and shareholders		(25,000)
Proceeds from U.S. Small Business Administration PPP loan payable	37,166
Common stock and warrants issued for cash		10,000
Contribution of capital by joint venture partner	50,000	700,000
Net cash provided by financing activities	772,166	1,018,250
Net increase in cash	41,171	45,393
Cash beginning of period	53,147	4,210
Cash end of period	94,318	49,603
Supplemental cash flows disclosures:
Interest paid
Taxes paid
Supplemental non-cash financing disclosures:
Initial recognition of right-of-use assets and operating lease liabilities upon adoption of ASC Topic 842	27,841
Reclassification of prepaid expenses to inventories	55,000
Conversion of loan payable from shareholder into common shares	30,000
Conversion of convertible note payable into common shares		$ 290,172

Basis of Presentation

Basis of Presentation	9 Months Ended
	Jun. 30, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	NOTE 1 – BASIS OF PRESENTATION Organization and Operations Wellness Center USA, Inc. (“WCUI” or the “Company”) was incorporated in June 2010 under the laws of the State of Nevada. The Company initially engaged in online sports and nutrition supplements marketing and distribution. The Company subsequently expanded into additional businesses within the healthcare and medical sectors through acquisitions, including Psoria-Shield Inc. (“PSI”) and StealthCo Inc. (“SCI”), d/b/a Stealth Mark, Inc. The Company currently operates in the following business segments: (i) distribution of targeted Ultra Violet (“UV”) phototherapy devices for dermatology; and (ii) authentication and encryption products and services. The segments are operated, respectively, through PSI and SCI. Basis of Presentation of Unaudited Financial Information The accompanying unaudited condensed consolidated financial statements of Wellness Center USA, Inc. and Subsidiaries (the “Company”) have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, all normal recurring adjustments considered necessary for a fair presentation have been included. Operating results for the nine months ended June 30, 2020 are not necessarily indicative of the results that may be expected for the year ending September 30, 2020. Going Concern The accompanying condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. As reflected in the accompanying condensed consolidated financial statements, the Company has not yet generated significant revenues and has incurred recurring net losses. During the nine months ended June 30, 2020, the Company incurred a net loss of $2,183,828 and used cash in operations of $730,995, and had a shareholders’ deficit of $2,168,793 as of June 30, 2020. In addition, $96,834 of payroll taxes are past due. These factors raise substantial doubt about the Company’s ability to continue as a going concern. The ability of the Company to continue as a going concern is dependent upon the Company’s ability to raise additional funds and implement its strategies. The financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern. In addition, the Company’s independent registered public accounting firm, in its report on the Company’s September 30, 2019 financial statements, has raised substantial doubt about the Company’s ability to continue as a going concern. At June 30, 2020, the Company had cash on hand in the amount of $94,318. The ability to continue as a going concern is dependent on the Company attaining and maintaining profitable operations in the future and raising additional capital soon to meet its obligations and repay its liabilities arising from normal business operations when they come due. Since inception, we have funded our operations primarily through equity and debt financings and we expect to continue to rely on these sources of capital in the future. During the nine months ended June 30, 2020, the Company received $772,166 through short-term loans and contributions of capital by a joint venture partner. No assurance can be given that any future financing will be available or, if available, that it will be on terms that are satisfactory to the Company. Even if the Company is able to obtain additional financing, it may contain undue restrictions on our operations, in the case of debt financing or cause substantial dilution for our stock holders, in case of equity financing.

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Jun. 30, 2020
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Consolidation The consolidated financial statements include the Company’s wholly owned subsidiaries and the accounts of its subsidiaries for which it was determined that Company has operational and management control. The Company’s consolidated subsidiaries and/or entities are as follows: Name of consolidated subsidiary or entity State or other jurisdiction of incorporation or organization Date of incorporation or formation (date of acquisition/disposition, if applicable) Attributable interest Psoria-Shield Inc. (“PSI”) The State of Florida June 17, 2009 (August 24, 2012) 51% StealthCo, Inc. (“StealthCo”) The State of Illinois March 18, 2014 100% Psoria Development Company LLC. (“PDC”) The State of Illinois January 15, 2015/November 15, 2018 50% NEO Phototherapy LLC (“NEO”) The State of Illinois December 2018 51% Protec Scientific, Inc (“Protec”) The State of New York April 2020 48% Use of Estimates The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the U.S requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the financial statement date, and reported amounts of revenue and expenses during the reporting period. Significant estimates are used in the valuation of accounts receivable and allowance for uncollectible amounts, inventory and obsolescence reserves, accruals for potential liabilities, valuations of stock-based compensation, realization of deferred tax assets, among others. Actual results could differ from these estimates. Income (Loss) Per Share Basic loss per share is computed by dividing net loss applicable to common stockholders by the weighted average number of outstanding common shares during the period. Diluted loss per share is computed by dividing the net loss applicable to common stockholders by the weighted average number of common shares outstanding plus the number of additional common shares that would have been outstanding if all dilutive potential common shares had been issued. For the nine months ended June 30, 2020 and 2019, the basic and diluted shares outstanding were the same, as potentially dilutive shares were considered anti-dilutive. At June 30, 2020 and 2019, the dilutive impact of outstanding stock options of 13,765,238 and 15,687,738 shares, respectively, and outstanding warrants for 67,634,049 and 66,832,049 shares, respectively, have been excluded because their impact on the loss per share is anti-dilutive. Revenue Recognition In May 2014, the FASB issued Accounting Standards Update (“ASU”) 2014-09, Revenue from Contracts with Customers (Topic 606). For trade sales, the Company generates its revenue from sales contracts with customers with revenues being generated upon the shipment of merchandise, or for c We sell our products through two main sales channels: 1) directly to customers who use our products (the “Direct Channel”) and 2) to distribution partners who resell our products (the “Indirect Channel”). Under the Direct Channel, we sell our products to and we receive payment directly from customers who purchase our products. Under our Indirect Channel, we have entered into distribution agreements that allow the distributors to sell our products and fulfill performance obligations under the agreements. We determine revenue recognition through the following steps: ● Identification of the contract, or contracts, with a customer ● Identification of the performance obligations in the contract ● Determination of the transaction price ● Allocation of the transaction price to the performance obligations in the contract ● Recognition of revenue when, or as, we satisfy a performance obligation. Revenue is generally recognized upon shipment or when a service has been completed, unless we have significant performance obligations for services still to be completed. We recognize revenue when a material reversal is no longer probable. Payments received before the relevant criteria for revenue recognition are satisfied are recorded as deferred revenue. There was no deferred revenue at June 30, 2020 and September 31, 2019. Non-controlling Interests Through November 2018, non-controlling interest represented the non-controlling interest holder’s proportionate share of the equity of the Company’s majority-owned subsidiary, PDC. Non-controlling interest is adjusted for the non-controlling interest holder’s proportionate share of the earnings or losses and other comprehensive income (loss), if any, and the non-controlling interest continues to be attributed its share of losses even if that attribution results in a deficit non-controlling interest balance. On November 15, 2018, PSI and TMA entered into a Withdraw and Mutual Release Agreement to terminate their joint venture agreement. On the date of termination, the non-controlling interest’s share of the accumulated losses of the joint venture totaled to $405,383. Upon termination, during the year ended September 30, 2019, the Company wrote-off the non-controlling interest’s share of the accumulated losses and recorded a loss from the deconsolidation of a non-controlling interest of $405,383. In December 2018, PSI entered into a Joint Venture Agreement with GEN2 to further development, marketing, licensing and/or sale of PSI technology and products. Pursuant to the Joint Venture Agreement, the venture will be conducted through NEO Phototherapy, Inc. (“NEO”). PSI and GEN2 will be the members of NEO, owning 50.5% and 36.0%, respectively, of the Units issued in connection with the organization of NEO. An additional 13.5% of such Units will be reserved for issuance as incentives for key employees and consultants. Until such shares are distributed, the Company controls 68% of the joint venture and GEN2 the remaining 32%. PSI and GEN2 will manage NEO’s day-to-day operations. PSI will contribute PSI technology to NEO and GEN2 will contribute $700,000. As of December 31, 2019, NEO’s operations required additional funding above the $700,000 documented in the agreement, and as of September 30, 2019, GEN2 had received $925,000 of investments to contribute to NEO. During the nine months ended June 30, 2020, an additional $50,000 was contributed by GEN2 to NEO. As of June 30, 2020, GEN2 had received $975,000 of investments to contribute to NEO. As of April 30, 2020, the Company controlled 51% of the joint venture, GEN2 controlled 39% and another individual controlled the remaining 10%. The Company recorded its proportionate share of the contributions received of $497,250 to additional paid-in-capital and $477,750 to non-controlling interest as of that date. Effective April 30, 2020, the joint venture with GEN2 was reorganized. GEN2 shareholders exchanged their common shares in GEN2, and the individual exchanged his membership interests in NEO, for common shares representing 49% ownership in PSI. The Company retained its common shares in PSI, which provides the Company a 51% economic interest in the PSI technology and products developed by the joint venture. During the three and nine months ended June 30, 2020, the entities recorded a combined loss of $71,442 and $161,604, respectively, relating to its operations, of which $35,007 and $79,186 was allocated to the non-controlling interest. Repayment of the $975,000 investment will begin through and upon the date which PSI has realized and retained cumulative net income/distributable cash in the amount of $300,000. PSI ownership consists of accredited investors, and investment participation of $750,000 from several WCUI officers and directors, including Calvin R. O’Harrow and Roy M. Harsch. At the end of May 2020, the Company’s subsidiary, PSI, agreed to become a majority shareholder in Protec Scientific, Inc. (“Protec”), subject to execution of a definitive agreement. Protec was formed in April 2020 by John Yorke for the purpose of designing, developing and marketing products that use spectral photonic emissions across a variety of applications. As of June 30, 2020, PSI had advanced $80,000 to Protec in furtherance of its agreement to acquire approximately 96% of Protec, with the Company’s derivative share being approximately 48%, based on its PSI ownership. The remaining 52% derivative share is to be attributed to PSI’s minority shareholders, based on their PSI ownership, and other investors. During the three months ended June 30, 2020, Protec recorded a loss of $79,926, of which $41,561 was allocated to the non-controlling interest. Subsequent to June 30, 2020, Protec received additional investments from non-affiliated investors. See Note 10 for additional information. Stock-Based Compensation The Company periodically grants stock options and warrants to employees and non-employees in non-capital raising transactions as compensation for services rendered. The Company accounts for stock option and stock warrant grants to employees based on the authoritative guidance provided by the Financial Accounting Standards Board where the value of the award is measured on the date of grant and recognized over the vesting period. The Company accounts for stock option and stock warrant grants to non-employees in accordance with the authoritative guidance of the Financial Accounting Standards Board where the value of the stock compensation is determined based upon the measurement date at either a) the date at which a performance commitment is reached, or b) at the date at which the necessary performance to earn the equity instruments is complete. Non-employee stock-based compensation charges generally are amortized over the vesting period on a straight-line basis. In certain circumstances where there are no future performance requirements by the non-employee, option or warrant grants are immediately vested and the total stock-based compensation charge is recorded in the period of the measurement date. The fair value of the Company’s common stock option and warrant grants are estimated using a Black-Scholes Merton option pricing model, which uses certain assumptions related to risk-free interest rates, expected volatility, expected life of the common stock options, estimated forfeitures and future dividends. Compensation expense is recorded based upon the value derived from the Black-Scholes option pricing model, and based on actual experience. The assumptions used in the Black-Scholes Merton option pricing model could materially affect compensation expense recorded in future periods. Leases In February 2016, the FASB issued ASU No. 2016-02, Leases. ASU 2016-02 requires a lessee to record a right of use asset and a corresponding lease liability on the balance sheet for all leases with terms longer than twelve months. ASU 2016-02 is effective for all interim and annual reporting periods beginning after December 15, 2018. Early adoption is permitted. A modified retrospective transition approach is required for lessees for leases existing at, or entered into after, the beginning of the earliest period presented in the financial statements. The Company adopted ASU 2016-02 effective October 1, 2019. As a result, we recorded right-of-use assets of $27,841, and lease liabilities of the same amount, as of that date. In accordance with ASU 2016-02, the right-of-use assets are being amortized over the life of the underlying leases, and monthly lease payments are being recorded as reductions to the lease liability and imputed interest expense. See Note 4 for additional information. Recently Issued Accounting Pronouncements In June 2016, the FASB issued ASU No. 2016-13, Credit Losses - Measurement of Credit Losses on Financial Instruments (“ASC 326”). The standard significantly changes how entities will measure credit losses for most financial assets, including accounts and notes receivables. The standard will replace today’s “incurred loss” approach with an “expected loss” model, under which companies will recognize allowances based on expected rather than incurred losses. Entities will apply the standard’s provisions as a cumulative-effect adjustment to retained earnings as of the beginning of the first reporting period in which the guidance is effective. The standard is effective for interim and annual reporting periods beginning after December 15, 2019. The adoption of ASU 2016-13 is not expected to have a material impact on the Company’s financial position, results of operations, and cash flows. Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or are not believed by management to have a material impact on the Company’s present or future consolidated financial statements.

Loans Payable from Officers and

Loans Payable from Officers and Shareholders	9 Months Ended
	Jun. 30, 2020
Debt Disclosure [Abstract]
Loans Payable from Officers and Shareholders	NOTE 3 – LOANS PAYABLE FROM OFFICERS AND SHAREHOLDERS As of September 30, 2019, loans payable from officers and shareholders of $399,250 were outstanding. During the nine months ended June 30, 2020, the Company borrowed $685,000 from its officers and shareholders. The loans have an interest rate of eight percent and are due one year from the date of issuance. During the three months ended June 30, 2020, one of the loan holders who is not an officer or director, converted his loan in the amount of $30,000 into 575,000 shares of the Company’s common stock. In connection with the conversion of the loan payable, the Company issued the loan holder a warrant to purchase 1,150,000 shares of common stock as an inducement to convert. The warrants have an exercise price of $0.07 per share and expire five years from the date of grant. The fair value of the warrants of $43,815 was recorded as a financing cost during the three months ended June 30, 2020 and was based on a probability affected Black-Scholes Merton pricing model with a stock price of $0.04, volatility of 187.0% and a risk-free rate of 0.20%. As of June 30, 2020, loans payable to officers and shareholders of $1,054,250 were outstanding. All of the loans are unsecured, have an interest rate of eight percent and are due one year from the date of issuance. As of June 30, 2020, the Company’s officers and directors had the following loans outstanding: Calvin O;Harrow - $544,250; Roy Harsch - $150,000; William Kingsford - $131,000; Paul Jones - $75,000; Douglas Samuelson - $30,000.

U.S. Small Business Administrat

U.S. Small Business Administration Loan Payable	9 Months Ended
	Jun. 30, 2020
U.s. Small Business Administration Loan Payable
U.S. Small Business Administration Loan Payable	NOTE 4 – U.S. SMALL BUSINESS ADMINISTRATION LOAN PAYABLE During the three months ended June 30, 2020, the Company’s subsidiary, PSI, entered into a loan agreement with the United States Small Business Administration (SBA) under which the Company borrowed $37,166. The loan is unsecured, accrues interest at 1.0% and is due on April 23, 2022. Beginning in October 2020, PSI is required to make monthly interest payments and all principal and unpaid interest is due in April 2022. If PSI meets certain criteria as defined in the agreement, the loan may be forgiven.

Lease Liabilities

Lease Liabilities	9 Months Ended
	Jun. 30, 2020
Leases [Abstract]
Lease Liabilities	NOTE 5 – LEASE LIABILITIES In February 2019, the Company’s PSI subsidiary entered into a 24-month non-cancellable lease for its office facilities that requires monthly payments of $1,800 through January 2021. The Company adopted ASU 2016-02, Leases, effective October 1, 2019, which requires a lessee to record a right-of-use asset and a corresponding lease liability at the inception of the lease initially measured at the present value of the lease payments. The Company classified the lease as an operating lease and determined that the value of the lease assets and liability at the adoption date was $27,841 using a discount rate of 4.00%. During the three and nine months ended June 30, 2020, the Company made payments of $5,245 and $15,584, respectively, towards the lease liability. As of June 30, 2020, lease liability amounted to $12,257. ASU 2016-02 requires recognition in the statement of operations of a single lease cost, calculated so that the cost of the lease is allocated over the lease term, generally on a straight-line basis. Rent expense for the three and nine months ended June 30, 2020 was $5,400 and $16,200, respectively. During the three and nine months ended June 30, 2020, the Company reflected amortization of right of use asset of $5,245 and $15,584, respectively, related to this lease, resulting in a net asset balance of $12,257 as of June 30, 2020.

Shareholders' Equity

Shareholders' Equity	9 Months Ended
	Jun. 30, 2020
Equity [Abstract]
Shareholders' Equity	NOTE 6 – SHAREHOLDERS’ EQUITY Restricted Stock Grants In April 2020, the Company’s Board of Directors approved the issuance of a combined total of 19,910,000 restricted shares of the Company’s common stock to its Officers and Directors. A total of 6,860,000 shares vested in April 2020, while 1,800,000 will vest monthly from April 2020 through March 2021, and 11,250,000 will vest monthly from April 2020 through March 2023. Of the 13,050,000 shares that vest over time, a total of 1,387,500 shares vested during the three months ended June 30, 2020. The following table summarizes restricted common stock activity: Number of Restricted Fair Value Weighted Non-vested, September 30, 2019 - $ - $ - Granted 19,910,000 597,300 0.03 Vested (8,247,500 ) (247,425 ) 0.03 Forfeited - - - Non-vested, June 30, 2020 11,662,500 $ 349,875 $ 0.03 Stock Options On December 22, 2010, the Company’s Board of Directors approved the adoption of the “2010 Non-Qualified Stock Option Plan” (“2010 Option Plan”) by unanimous consent. The 2010 Option Plan was initiated to encourage and enable officers, directors, consultants, advisors and key employees of the Company to acquire and retain a proprietary interest in the Company by ownership of its common stock. A total of 7,500,000 of the authorized shares of the Company’s common stock may be subject to, or issued pursuant to, the terms of the plan. Effective January 1, 2018, the Board of Directors approved to increase the number of authorized shares of the Company’s common stock that may be subject to, or issued pursuant to, the terms of the plan from 7,500,000 to 30,000,000. The Company’s policy is to recognize compensation cost for awards with only service conditions and a graded vesting schedule on a straight-line basis over the requisite service period for the entire award. Additionally, the Company’s policy is to issue new shares of common stock to satisfy stock option exercises. The Company applied fair value accounting for all share based payments awards. The fair value of each option granted is estimated on the date of grant using the Black-Scholes option-pricing model. The table below summarizes the Company’s stock option activities for the nine months ended June 30, 2020: Number of Option Shares Exercise Price Range Per Share Weighted Average Exercise Price Balance, September 30, 2019 15,237,738 $ 0.03 - 2.00 $ 0.27 Granted 4,375,000 0.04 0.04 Cancelled (4,910,000 ) 0.14 – 0.30 0.14 Exercised - - - Expired (937,500 ) 0.11 - 0.25 0.16 Balance, June 30, 2020 13,765,238 $ 0.03 – 2.00 $ 0.24 Vested and exercisable, June 30, 2020 9,877,738 $ 0.03 – 2.00 $ 0.32 Unvested, June 30, 2020 3,887,500 $ 0.04 - 0.14 $ 0.04 During the period ended June 30, 2020, the Company’s Board of Directors approved the cancellation of stock options to purchase 3,360,000 shares of the Company’s common stock with an exercise prices of $0.14 and $0.30 per share that had vested as of March 31, 2020, and 1,550,000 shares with an exercise price of $0.14 per share that were set to vest monthly from April 2020 through March 2021. All of the cancelled options were held by the Company’s Officers and Directors. The Board approved the grant of stock options to its Chief Executive Officer to purchase 4,250,000 shares with an exercise price of $0.04 per share that expire ten years from the date of grant. The fair value of the shares was determined to be $127,500 as of the date of grant based on a Black-Scholes option model. A total of 500,000 shares vested during the three months ended June 30, 2020 and 3,750,000 shares will vest monthly over three years from April 2020 through March 2023 The Board approved the following modifications relating to the Chief Executive Officer’s options: a. Repricing of stock options to purchase 1,200,000 shares with an exercise price of $0.14 per share to $0.04 per share that had vested as of March 31, 2020, b. Repricing of stock options to purchase 600,000 shares with an exercise price of $0.14 per share to $0.04 per share that were set to vest monthly from April 2020 through March 2021. c. Extend the expiration of the options to ten years from the date of grant, rather than the five-year expiration the shares initially had. The incremental fair value of the options resulting from the modifications was $22,680 that was recognized as an expense during the three months ended June 30, 2020. In addition to the options granted to the Company’s Chief Executive Officer noted above, during the nine months ended June 30, 2020, the Company granted options to an employee to purchase a total of 125,000 shares of its common stock with an aggregate fair value of $4,688. The options have an exercise price of $0.04 per share and expire five years from the date of grant. The shares vested on the date of grant. The Company valued the options using a Black-Scholes option pricing model. The assumptions used for all of the options granted during the nine months ended June 30, 2020 are as follows: Exercise price $ 0.04 Expected dividends - Expected volatility 157.6% – 182.9 % Risk free interest rate 0.26 % - 1.60 % Expected life of options 2.5 During the three and nine months ended June 30, 2020, the Company recorded $66,306 and $197,844 of stock compensation for the value of all outstanding options, and as of June 30, 2020, unvested compensation of $107,645 remained that will be amortized over the remaining vesting period. The aggregate intrinsic value for option shares outstanding at June 30, 2020 was $625. As of June 30, 2020, there were 16,234,762 shares of stock options remaining available for issuance under the 2010 Plan. The following table summarizes information concerning outstanding and exercisable options as of June 30, 2020: Options Outstanding Options Exercisable Range of Exercise Prices Number Outstanding Average Remaining Contractual Life Weighted Average Exercise Price Number Exercisable Average Remaining Contractual Life Weighted Average $ 0.06 - 0.39 12,302,738 3.34 $ 0.09 8,415,238 2.70 $ 0.12 0.40 - 0.99 62,500 1.75 0.40 62,500 1.75 0.40 1.00 - 1.99 750,000 0.50 1.00 750,000 0.50 1.00 2.00 650,000 0.50 2.00 650,000 0.50 2.00 $ 0.06 - 2.00 13,765,238 3.05 $ 0.24 9,877,738 2.38 $ 0.32 Stock Warrants The table below summarizes the Company’s warrants activities for the nine months ended June 30, 2020: Number of Warrant Shares Exercise Price Range Per Share Weighted Average Exercise Price Balance, September 30, 2019 66,484,049 $ 0.12 - 0.40 $ 0.17 Granted 1,150,000 0.07 0.07 Cancelled - - - Exercised - - - Expired - - - Balance, June 30, 2020 67,634,049 $ 0.07 - 0.40 $ 0.16 Vested and exercisable, June 30, 2020 67,634,049 $ 0.07 - 0.40 $ 0.16 Effective January 1, 2020, the Company’s Board of Directors approved the extension of the Company’s unexpired stock warrants as of December 31, 2019, by an additional one year period. This change affected approximately 66,000,000 warrant shares and approximately 20,000,000 warrant shares that were set to expire by the year ending September 30, 2020. The 20,000,000 warrant shares that were set to expire by September 30, 2020, had exercise prices ranging from $0.15 per share to $0.25 per share. The 66,000,000 warrant shares had exercise prices ranging from $0.12 per share to $0.40 per share. The incremental fair value of the warrants resulting from modification was $507,265 and was recognized as an expense during the nine months ended June 30, 2020. There was no aggregate intrinsic value for warrant shares outstanding at June 30, 2020. The following table summarizes information concerning outstanding and exercisable warrants as of June 30, 2020: Warrants Outstanding Warrants Exercisable Range of Exercise Prices Number Outstanding Average Remaining Contractual Life Weighted Average Exercise Price Number Exercisable Average Remaining Contractual Life Weighted Average Exercise Price $ 0.12 – 0.20 60,429,384 2.20 $ 0.15 60,429,384 2.20 $ 0.15 0.21 – 0.40 7,204,665 1.13 0.26 7,204,665 1.13 0.26 $ 0.12 – 0.40 67,634,049 2.09 $ 0.16 67,634,049 2.09 $ 0.16

Segment Reporting

Segment Reporting	9 Months Ended
	Jun. 30, 2020
Segment Reporting [Abstract]
Segment Reporting	NOTE 7 – SEGMENT REPORTING Reportable segments are components of an enterprise about which separate financial information is available and that is evaluated regularly by the chief operating decision maker in deciding how to allocate resources and in assessing performance. The Company’s reportable segments are based on products and services, geography, legal structure, management structure, or any other manner in which management disaggregates a company. The Company operates in the following business segments: (i) Medical Devices: (ii) Authentication and Encryption Products and Services: The detailed segment information of the Company is as follows: Assets By Segment June 30, 2020 Corporate Medical Devices Authentication and Encryption Total ASSETS Current Assets Cash $ 39,770 $ 51,402 $ 3,146 $ 94,318 Accounts receivable - - 5,000 5,000 Inventories - 72,075 - 72,075 Prepaid expenses and other current assets 500 - - 500 Total current assets 40,270 123,477 8,146 171,893 Right-of-use asset - 12,257 - 12,257 Total other assets - 12,257 - 12,257 TOTAL ASSETS $ 40,270 $ 135,734 $ 8,146 $ 184,150 Operations by Segment For the Three Months Ended June 30, 2020 and 2019 For the Three Months Ended June 30, 2020 Corporate Medical Devices Authentication and Encryption Total Sales: Trade $ - $ - $ - $ - Consulting services - - - - Total Sales - - - - Cost of goods sold - - - - Gross profit - - - - Operating expenses 620,650 208,047 (15,317 ) 813,380 Income (loss) from operations $ (620,650 ) $ (208,047 ) $ 15,317 $ (813,380 ) For the Three Months Ended June 30, 2019 Corporate Medical Devices Authentication and Encryption Total Sales: Trade $ - $ - $ 3,108 $ 3,108 Consulting services - - 4,517 4,517 Total Sales - - 7,625 7,625 Cost of goods sold - - 4,575 4,575 Gross profit - - 3,050 3,050 Operating expenses 175,784 95,306 133,120 404,210 Loss from operations $ (175,784 ) $ (95,306 ) $ (130,070 ) $ (401,160 ) Operations by Segment For the Nine Months Ended June 30, 2020 and 2019 For the Nine Months Ended June 30, 2020 Corporate Medical Devices Authentication and Encryption Total Sales: Trade $ - $ - $ 5,000 $ 5,000 Consulting services - - - - Total Sales - - 5,000 5,000 Cost of goods sold - - - - Gross profit - - 5,000 5,000 Operating expenses 861,611 590,158 122,014 1,573,783 Loss from operations $ (861,611 ) $ (590,158 ) $ (117,014 ) $ (1,568,783 ) For the Nine Months Ended June 30, 2019 Corporate Medical Devices Authentication and Encryption Total Sales: Trade $ - $ - $ 19,508 $ 19,508 Consulting services - - 13,867 13,867 Total Sales - - 33,375 33,375 Cost of goods sold - - 20,025 20,025 Gross profit - - 13,350 13,350 Operating expenses 716,900 399,111 299,656 1,415,667 Loss from operations $ (716,900 ) $ (399,111 ) $ (286,306 ) $ (1,402,317 )

Legal Matters

Legal Matters	9 Months Ended
	Jun. 30, 2020
Commitments and Contingencies Disclosure [Abstract]
Legal Matters	NOTE 8 – LEGAL MATTERS The Company is periodically engaged in legal proceedings arising from and relating to its business operations. During the period covered by this Report, we have attempted to preserve revenue and reduce operating expenses through actions including, but not limited to, facilities consolidation and staff reductions, with the hope of reaching negotiated transactions with lessors, employees and other third parties. Such actions have resulted in disputes with and claims by such parties which, if not resolved through negotiations, may impact negatively the Company’s ability to continue as a going concern. Through December 31, 2019, we had negotiated settlement of all but $89,302 in ex-employee wage and benefits claims, with agreement to pay such remaining amount, together with interest at the rate of 4% per annum on the principal amount from time to time outstanding, when and as cash flow permits. One of the employees claims additional amounts due for certain statutory damages under the Illinois Wage Payment and Collection which currently could exceed $25,600 and would increase at the rate of 2% of the wages due per month plus attorneys’ fees if the employee elects to file suit for a violation of the Act and is successful in obtaining a judgment on his claim. During the nine months ended June 30, 2020, the Company paid $49,393 to one of the employees who had a claim against the Company. On or about April 1, 2020, the Company received notice from the Illinois Department of Labor that our ex-CEO had filed a wage claim for $179,543. The Company has responded to the claim denying any amount is payable. The claim relates to services claimed to have been performed during the period in which such ex-CEO admitted in a guilty plea to violation of certain federal criminal laws involving, among other things, manipulation of the price of our stock and engaging in undisclosed sales of our stock resulting in his receipt of proceeds exceeding $600,000. Our response relies upon settled Illinois law that a willful, deliberate, and repeated breach of fiduciary duty by a corporate officer and/or director, as evidenced by a guilty plea in a criminal proceeding, justifies a complete forfeiture of officer and director’s compensation. On or about June 29, 2020, the Company received notice that a suit had been filed in the Circuit Court of Cook County alleging our failure to pay Base Rent and abandonment of certain office space in Hoffman Estates, Illinois, as noted in the following Note 9.

Commitments

Commitments	9 Months Ended
	Jun. 30, 2020
Commitments and Contingencies Disclosure [Abstract]
Commitments	NOTE 9 – COMMITMENTS Other Leases The Company leased its corporate office facility in Hoffman Estates, Illinois pursuant to a non-cancellable lease initiated in July 2016 and expiring February 28, 2024. The lease terms require a monthly payment of approximately $11,000. The Company vacated the facility in April 2019, in favor of its present facilities in Tucson AZ, which are provided by a shareholder on a rent-free basis. The Company is in negotiations with the owners regarding the settlement of its lease obligations and expects that the property will be subleased or a settlement with the landlord will be reached at an amount significantly less than the remaining payment obligations. At the date of abandonment, the Company had a remaining lease obligation of $631,587. During the year ended September 30, 2019, the Company recorded an accrual for its estimate for the potential settlement of this matter and wrote-off its $15,000 security deposit relating to the lease. On or about June 29, 2020, we received notice that Hanover Hoffman Estates, LLC (“HHE”), filed case number 2020L006092 in the Circuit Court of Cook County alleging our failure to pay Base Rent and abandonment of certain office space in Hoffman Estates, Illinois subject to a Commercial Lease dated May 26, 2016. HHE seeks at least $672,878 in base rent and other amounts under the lease, as well as treble damages from our ex-CEO and two past Directors who were serving on our Board as of the date of the lease. We are currently evaluating the allegations, defenses and alternate actions. During the three and nine months ended June 30, 2020, the Company recorded an additional expense of $334,557 and $438,296, respectively, relating to the lease obligation, and recorded the full amount of the claim due as of June 30, 2020. Commencing on October 1, 2016, the Company’s wholly-owned subsidiary, StealthCo, entered into a non-cancellable lease agreement to lease its office facilities in Oak Ridge, Tennessee. The term of the lease is five years and expires September 30, 2021. On January 6, 2020, the Company entered into an agreement with the owners to terminate the agreement effective January 1, 2020. Under the agreement, the Company agreed to pay $11,000 and abandon certain Company property as documented in the agreement. During the nine months ended June 30, 2020, the $11,000 was paid by the Company.

Subsequent Events

Subsequent Events	9 Months Ended
	Jun. 30, 2020
Subsequent Events [Abstract]
Subsequent Events	NOTE 10 – SUBSEQUENT EVENTS Subsequent to June 30, 2020, Protec Scientific, Inc. (see Note 2) received $95,000 of investments, of which $75,000 was received from non-affiliated investors. Due to those investments, as of the date of this filing, PSI’s ownership in Protec was reduced to approximately 86% and the Company’s derivative ownership was reduced to approximately 43%.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Jun. 30, 2020
Accounting Policies [Abstract]
Basis of Consolidation	Basis of Consolidation The consolidated financial statements include the Company’s wholly owned subsidiaries and the accounts of its subsidiaries for which it was determined that Company has operational and management control. The Company’s consolidated subsidiaries and/or entities are as follows: Name of consolidated subsidiary or entity State or other jurisdiction of incorporation or organization Date of incorporation or formation (date of acquisition/disposition, if applicable) Attributable interest Psoria-Shield Inc. (“PSI”) The State of Florida June 17, 2009 (August 24, 2012) 51% StealthCo, Inc. (“StealthCo”) The State of Illinois March 18, 2014 100% Psoria Development Company LLC. (“PDC”) The State of Illinois January 15, 2015/November 15, 2018 50% NEO Phototherapy LLC (“NEO”) The State of Illinois December 2018 51% Protec Scientific, Inc (“Protec”) The State of New York April 2020 48%
Use of Estimates	Use of Estimates The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the U.S requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the financial statement date, and reported amounts of revenue and expenses during the reporting period. Significant estimates are used in the valuation of accounts receivable and allowance for uncollectible amounts, inventory and obsolescence reserves, accruals for potential liabilities, valuations of stock-based compensation, realization of deferred tax assets, among others. Actual results could differ from these estimates.
Income (Loss) Per Share	Income (Loss) Per Share Basic loss per share is computed by dividing net loss applicable to common stockholders by the weighted average number of outstanding common shares during the period. Diluted loss per share is computed by dividing the net loss applicable to common stockholders by the weighted average number of common shares outstanding plus the number of additional common shares that would have been outstanding if all dilutive potential common shares had been issued. For the nine months ended June 30, 2020 and 2019, the basic and diluted shares outstanding were the same, as potentially dilutive shares were considered anti-dilutive. At June 30, 2020 and 2019, the dilutive impact of outstanding stock options of 13,765,238 and 15,687,738 shares, respectively, and outstanding warrants for 67,634,049 and 66,832,049 shares, respectively, have been excluded because their impact on the loss per share is anti-dilutive.
Revenue Recognition	Revenue Recognition In May 2014, the FASB issued Accounting Standards Update (“ASU”) 2014-09, Revenue from Contracts with Customers (Topic 606). For trade sales, the Company generates its revenue from sales contracts with customers with revenues being generated upon the shipment of merchandise, or for c We sell our products through two main sales channels: 1) directly to customers who use our products (the “Direct Channel”) and 2) to distribution partners who resell our products (the “Indirect Channel”). Under the Direct Channel, we sell our products to and we receive payment directly from customers who purchase our products. Under our Indirect Channel, we have entered into distribution agreements that allow the distributors to sell our products and fulfill performance obligations under the agreements. We determine revenue recognition through the following steps: ● Identification of the contract, or contracts, with a customer ● Identification of the performance obligations in the contract ● Determination of the transaction price ● Allocation of the transaction price to the performance obligations in the contract ● Recognition of revenue when, or as, we satisfy a performance obligation. Revenue is generally recognized upon shipment or when a service has been completed, unless we have significant performance obligations for services still to be completed. We recognize revenue when a material reversal is no longer probable. Payments received before the relevant criteria for revenue recognition are satisfied are recorded as deferred revenue. There was no deferred revenue at June 30, 2020 and September 31, 2019.
Non-controlling Interests	Non-controlling Interests Through November 2018, non-controlling interest represented the non-controlling interest holder’s proportionate share of the equity of the Company’s majority-owned subsidiary, PDC. Non-controlling interest is adjusted for the non-controlling interest holder’s proportionate share of the earnings or losses and other comprehensive income (loss), if any, and the non-controlling interest continues to be attributed its share of losses even if that attribution results in a deficit non-controlling interest balance. On November 15, 2018, PSI and TMA entered into a Withdraw and Mutual Release Agreement to terminate their joint venture agreement. On the date of termination, the non-controlling interest’s share of the accumulated losses of the joint venture totaled to $405,383. Upon termination, during the year ended September 30, 2019, the Company wrote-off the non-controlling interest’s share of the accumulated losses and recorded a loss from the deconsolidation of a non-controlling interest of $405,383. In December 2018, PSI entered into a Joint Venture Agreement with GEN2 to further development, marketing, licensing and/or sale of PSI technology and products. Pursuant to the Joint Venture Agreement, the venture will be conducted through NEO Phototherapy, Inc. (“NEO”). PSI and GEN2 will be the members of NEO, owning 50.5% and 36.0%, respectively, of the Units issued in connection with the organization of NEO. An additional 13.5% of such Units will be reserved for issuance as incentives for key employees and consultants. Until such shares are distributed, the Company controls 68% of the joint venture and GEN2 the remaining 32%. PSI and GEN2 will manage NEO’s day-to-day operations. PSI will contribute PSI technology to NEO and GEN2 will contribute $700,000. As of December 31, 2019, NEO’s operations required additional funding above the $700,000 documented in the agreement, and as of September 30, 2019, GEN2 had received $925,000 of investments to contribute to NEO. During the nine months ended June 30, 2020, an additional $50,000 was contributed by GEN2 to NEO. As of June 30, 2020, GEN2 had received $975,000 of investments to contribute to NEO. As of April 30, 2020, the Company controlled 51% of the joint venture, GEN2 controlled 39% and another individual controlled the remaining 10%. The Company recorded its proportionate share of the contributions received of $497,250 to additional paid-in-capital and $477,750 to non-controlling interest as of that date. Effective April 30, 2020, the joint venture with GEN2 was reorganized. GEN2 shareholders exchanged their common shares in GEN2, and the individual exchanged his membership interests in NEO, for common shares representing 49% ownership in PSI. The Company retained its common shares in PSI, which provides the Company a 51% economic interest in the PSI technology and products developed by the joint venture. During the three and nine months ended June 30, 2020, the entities recorded a combined loss of $71,442 and $161,604, respectively, relating to its operations, of which $35,007 and $79,186 was allocated to the non-controlling interest. Repayment of the $975,000 investment will begin through and upon the date which PSI has realized and retained cumulative net income/distributable cash in the amount of $300,000. PSI ownership consists of accredited investors, and investment participation of $750,000 from several WCUI officers and directors, including Calvin R. O’Harrow and Roy M. Harsch. In May 2020, the Company’s subsidiary, PSI, agreed to become a majority shareholder in Protec Scientific, Inc. (“Protec”), a company formed in April 2020 by John Yorke for the purpose of designing, developing and marketing products that use spectral photonic emissions across a variety of applications. As of June 30, 2020, PSI had advanced $80,000 to Protec in furtherance of its agreement to acquire approximately 96% of Protec, with the Company’s derivative share being approximately 48%, based on its PSI ownership. The remaining 52% derivative share is to be attributed to PSI’s minority shareholders, based on their PSI ownership, and other investors. During the three months ended June 30, 2020, Protec recorded a loss of $79,926, of which $41,561 was allocated to the non-controlling interest. Subsequent to June 30, 2020, Protec received additional investments from non-affiliated investors. See Note 10 for additional information.
Stock-based Compensation	Stock-Based Compensation The Company periodically grants stock options and warrants to employees and non-employees in non-capital raising transactions as compensation for services rendered. The Company accounts for stock option and stock warrant grants to employees based on the authoritative guidance provided by the Financial Accounting Standards Board where the value of the award is measured on the date of grant and recognized over the vesting period. The Company accounts for stock option and stock warrant grants to non-employees in accordance with the authoritative guidance of the Financial Accounting Standards Board where the value of the stock compensation is determined based upon the measurement date at either a) the date at which a performance commitment is reached, or b) at the date at which the necessary performance to earn the equity instruments is complete. Non-employee stock-based compensation charges generally are amortized over the vesting period on a straight-line basis. In certain circumstances where there are no future performance requirements by the non-employee, option or warrant grants are immediately vested and the total stock-based compensation charge is recorded in the period of the measurement date. The fair value of the Company’s common stock option and warrant grants are estimated using a Black-Scholes Merton option pricing model, which uses certain assumptions related to risk-free interest rates, expected volatility, expected life of the common stock options, estimated forfeitures and future dividends. Compensation expense is recorded based upon the value derived from the Black-Scholes option pricing model, and based on actual experience. The assumptions used in the Black-Scholes Merton option pricing model could materially affect compensation expense recorded in future periods.
Leases	Leases In February 2016, the FASB issued ASU No. 2016-02, Leases. ASU 2016-02 requires a lessee to record a right of use asset and a corresponding lease liability on the balance sheet for all leases with terms longer than twelve months. ASU 2016-02 is effective for all interim and annual reporting periods beginning after December 15, 2018. Early adoption is permitted. A modified retrospective transition approach is required for lessees for leases existing at, or entered into after, the beginning of the earliest period presented in the financial statements. The Company adopted ASU 2016-02 effective October 1, 2019. As a result, we recorded right-of-use assets of $27,841, and lease liabilities of the same amount, as of that date. In accordance with ASU 2016-02, the right-of-use assets are being amortized over the life of the underlying leases, and monthly lease payments are being recorded as reductions to the lease liability and imputed interest expense. See Note 4 for additional information.
Recently Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements In June 2016, the FASB issued ASU No. 2016-13, Credit Losses - Measurement of Credit Losses on Financial Instruments (“ASC 326”). The standard significantly changes how entities will measure credit losses for most financial assets, including accounts and notes receivables. The standard will replace today’s “incurred loss” approach with an “expected loss” model, under which companies will recognize allowances based on expected rather than incurred losses. Entities will apply the standard’s provisions as a cumulative-effect adjustment to retained earnings as of the beginning of the first reporting period in which the guidance is effective. The standard is effective for interim and annual reporting periods beginning after December 15, 2019. The adoption of ASU 2016-13 is not expected to have a material impact on the Company’s financial position, results of operations, and cash flows. Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or are not believed by management to have a material impact on the Company’s present or future consolidated financial statements.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	9 Months Ended
	Jun. 30, 2020
Accounting Policies [Abstract]
Schedule of Company's Consolidated Subsidiaries	The Company’s consolidated subsidiaries and/or entities are as follows: Name of consolidated subsidiary or entity State or other jurisdiction of incorporation or organization Date of incorporation or formation (date of acquisition/disposition, if applicable) Attributable interest Psoria-Shield Inc. (“PSI”) The State of Florida June 17, 2009 (August 24, 2012) 51% StealthCo, Inc. (“StealthCo”) The State of Illinois March 18, 2014 100% Psoria Development Company LLC. (“PDC”) The State of Illinois January 15, 2015/November 15, 2018 50% NEO Phototherapy LLC (“NEO”) The State of Illinois December 2018 51% Protec Scientific, Inc (“Protec”) The State of New York April 2020 48%

Shareholders' Equity (Tables)

Shareholders' Equity (Tables)	9 Months Ended
	Jun. 30, 2020
Equity [Abstract]
Summary of Restricted Common Stock	The following table summarizes restricted common stock activity: Number of Restricted Fair Value Weighted Non-vested, September 30, 2019 - $ - $ - Granted 19,910,000 597,300 0.03 Vested (8,247,500 ) (247,425 ) 0.03 Forfeited - - - Non-vested, June 30, 2020 11,662,500 $ 349,875 $ 0.03
Schedule of Stock Option Activity	The table below summarizes the Company’s stock option activities for the nine months ended June 30, 2020: Number of Option Shares Exercise Price Range Per Share Weighted Average Exercise Price Balance, September 30, 2019 15,237,738 $ 0.03 - 2.00 $ 0.27 Granted 4,375,000 0.04 0.04 Cancelled (4,910,000 ) 0.14 – 0.30 0.14 Exercised - - - Expired (937,500 ) 0.11 - 0.25 0.16 Balance, June 30, 2020 13,765,238 $ 0.03 – 2.00 $ 0.24 Vested and exercisable, June 30, 2020 9,877,738 $ 0.03 – 2.00 $ 0.32 Unvested, June 30, 2020 3,887,500 $ 0.04 - 0.14 $ 0.04
Schedule of Assumptions Used for Options Granted	The assumptions used for all of the options granted during the nine months ended June 30, 2020 are as follows: Exercise price $ 0.04 Expected dividends - Expected volatility 157.6% – 182.9 % Risk free interest rate 0.26 % - 1.60 % Expected life of options 2.5
Schedule of Outstanding and Exercisable Options by Exercise Price Range	The following table summarizes information concerning outstanding and exercisable options as of June 30, 2020: Options Outstanding Options Exercisable Range of Exercise Prices Number Outstanding Average Remaining Contractual Life Weighted Average Exercise Price Number Exercisable Average Remaining Contractual Life Weighted Average $ 0.06 - 0.39 12,302,738 3.34 $ 0.09 8,415,238 2.70 $ 0.12 0.40 - 0.99 62,500 1.75 0.40 62,500 1.75 0.40 1.00 - 1.99 750,000 0.50 1.00 750,000 0.50 1.00 2.00 650,000 0.50 2.00 650,000 0.50 2.00 $ 0.06 - 2.00 13,765,238 3.05 $ 0.24 9,877,738 2.38 $ 0.32
Schedule of Warrant Activity	The table below summarizes the Company’s warrants activities for the nine months ended June 30, 2020: Number of Warrant Shares Exercise Price Range Per Share Weighted Average Exercise Price Balance, September 30, 2019 66,484,049 $ 0.12 - 0.40 $ 0.17 Granted 1,150,000 0.07 0.07 Cancelled - - - Exercised - - - Expired - - - Balance, June 30, 2020 67,634,049 $ 0.07 - 0.40 $ 0.16 Vested and exercisable, June 30, 2020 67,634,049 $ 0.07 - 0.40 $ 0.16
Schedule of Outstanding and Exercisable Warrants by Exercise Price Range	The following table summarizes information concerning outstanding and exercisable warrants as of June 30, 2020: Warrants Outstanding Warrants Exercisable Range of Exercise Prices Number Outstanding Average Remaining Contractual Life Weighted Average Exercise Price Number Exercisable Average Remaining Contractual Life Weighted Average Exercise Price $ 0.12 – 0.20 60,429,384 2.20 $ 0.15 60,429,384 2.20 $ 0.15 0.21 – 0.40 7,204,665 1.13 0.26 7,204,665 1.13 0.26 $ 0.12 – 0.40 67,634,049 2.09 $ 0.16 67,634,049 2.09 $ 0.16

Segment Reporting (Tables)

Segment Reporting (Tables)	9 Months Ended
	Jun. 30, 2020
Segment Reporting [Abstract]
Schedule of Assets of Reportable Segments	The detailed segment information of the Company is as follows: Assets By Segment June 30, 2020 Corporate Medical Devices Authentication and Encryption Total ASSETS Current Assets Cash $ 39,770 $ 51,402 $ 3,146 $ 94,318 Accounts receivable - - 5,000 5,000 Inventories - 72,075 - 72,075 Prepaid expenses and other current assets 500 - - 500 Total current assets 40,270 123,477 8,146 171,893 Right-of-use asset - 12,257 - 12,257 Total other assets - 12,257 - 12,257 TOTAL ASSETS $ 40,270 $ 135,734 $ 8,146 $ 184,150
Schedule of Operations of Reportable Segments	Operations by Segment For the Three Months Ended June 30, 2020 and 2019 For the Three Months Ended June 30, 2020 Corporate Medical Devices Authentication and Encryption Total Sales: Trade $ - $ - $ - $ - Consulting services - - - - Total Sales - - - - Cost of goods sold - - - - Gross profit - - - - Operating expenses 620,650 208,047 (15,317 ) 813,380 Income (loss) from operations $ (620,650 ) $ (208,047 ) $ 15,317 $ (813,380 ) For the Three Months Ended June 30, 2019 Corporate Medical Devices Authentication and Encryption Total Sales: Trade $ - $ - $ 3,108 $ 3,108 Consulting services - - 4,517 4,517 Total Sales - - 7,625 7,625 Cost of goods sold - - 4,575 4,575 Gross profit - - 3,050 3,050 Operating expenses 175,784 95,306 133,120 404,210 Loss from operations $ (175,784 ) $ (95,306 ) $ (130,070 ) $ (401,160 ) Operations by Segment For the Nine Months Ended June 30, 2020 and 2019 For the Nine Months Ended June 30, 2020 Corporate Medical Devices Authentication and Encryption Total Sales: Trade $ - $ - $ 5,000 $ 5,000 Consulting services - - - - Total Sales - - 5,000 5,000 Cost of goods sold - - - - Gross profit - - 5,000 5,000 Operating expenses 861,611 590,158 122,014 1,573,783 Loss from operations $ (861,611 ) $ (590,158 ) $ (117,014 ) $ (1,568,783 ) For the Nine Months Ended June 30, 2019 Corporate Medical Devices Authentication and Encryption Total Sales: Trade $ - $ - $ 19,508 $ 19,508 Consulting services - - 13,867 13,867 Total Sales - - 33,375 33,375 Cost of goods sold - - 20,025 20,025 Gross profit - - 13,350 13,350 Operating expenses 716,900 399,111 299,656 1,415,667 Loss from operations $ (716,900 ) $ (399,111 ) $ (286,306 ) $ (1,402,317 )

Basis of Presentation (Details

Basis of Presentation (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019	Mar. 31, 2020	Sep. 30, 2019	Mar. 31, 2019	Sep. 30, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Entity incorporation, state country name			Nevada
Net loss	$ (895,626)	$ (515,832)	$ (2,183,828)	$ (1,674,230)
Cash used in operations			(730,995)	(972,857)
Shareholders' deficit	(2,168,793)	$ (1,002,306)	(2,168,793)	$ (1,002,306)	$ (1,683,393)	$ (1,083,994)	$ (1,078,563)	$ (825,160)
Payroll taxes due	96,834		96,834			102,834
Cash on hand	$ 94,318		94,318			$ 53,147
Proceeds from short-term loans and contributions of capital by joint venture partner			$ 772,166

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details Narrative) - USD ($)	Nov. 15, 2018	May 30, 2020	Dec. 31, 2019	Dec. 31, 2018	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019	Sep. 30, 2019	Apr. 30, 2020	Oct. 02, 2019
Deferred revenue
Non-controlling interest's share of accumulated losses of joint venture	$ 405,383
Loss from deconsolidation of non-controlling interest								$ 405,383	405,383
Non-controlling interest, description			Pursuant to the Joint Venture Agreement, the venture will be conducted through NEO Phototherapy, Inc. ("NEO"). PSI and GEN2 will be the members of NEO, owning 50.5% and 36.0%, respectively, of the Units issued in connection with the organization of NEO. An additional 13.5% of such Units will be reserved for issuance as incentives for key employees and consultants. Until such shares are distributed, the Company controls 68% of the joint venture and GEN2 the remaining 32%. PSI and GEN2 will manage NEO's day-to-day operations. PSI will contribute PSI technology to NEO and GEN2 will contribute $700,000. As of December 31, 2019, NEO's operations required additional funding above the $700,000 documented in the agreement, and as of September 30, 2019, GEN2 had received $925,000 of investments to contribute to NEO. During the nine months ended June 30, 2020, an additional $50,000 was contributed by GEN2 to NEO. As of June 30, 2020, GEN2 had received $975,000 of investments to contribute to NEO. As of April 30, 2020, the Company controlled 51% of the joint venture, GEN2 controlled 39% and another individual controlled the remaining 10%. The Company recorded its proportionate share of the contributions received of $497,250 to additional paid-in-capital and $477,750 to non-controlling interest as of that date. Effective April 30, 2020, the joint venture with GEN2 was reorganized. GEN2 shareholders exchanged their common shares in GEN2, and the individual exchanged his membership interests in NEO, for common shares representing 49% ownership in PSI. The Company retained its common shares in PSI, which provides the Company a 51% economic interest in the PSI technology and products developed by the joint venture. During the three and nine months ended June 30, 2020, the entities recorded a combined loss of $71,442 and $161,604, respectively, relating to its operations, of which $35,007 and $79,186 was allocated to the non-controlling interest. Repayment of the $975,000 investment will begin through and upon the date which PSI has realized and retained cumulative net income/distributable cash in the amount of $300,000.
Contributed capital			$ 700,000
Joint venture percentage					51.00%		51.00%
Operating loss					$ (813,380)	$ (401,160)	$ (1,568,783)	$ (1,402,317)
Additional paid-in capital					24,843,353		24,843,353		23,777,647
Non-controlling interest					296,902		296,902		393,149
Distributable cash					300,000		300,000
Right-of-use assets					12,257		12,257				$ 27,841
Lease liabilities					12,257		12,257				$ 27,841
NEO [Member]
Contributed capital							50,000
Additional funding							700,000
GEN2 [Member]
Investments to others					$ 975,000		$ 975,000		$ 925,000
Joint venture percentage					39.00%		39.00%			49.00%
Employees and Consultants [Member]
Additional units reserved for issuance				13.50%
Individual [Member]
Joint venture percentage					10.00%		10.00%			51.00%
Protec Scientific, Inc. [Member]
Operating loss							$ 79,926
Additional paid-in capital					$ 41,561		$ 41,561
Acquisition description		In May 2020, the Company's subsidiary, PSI, agreed to become a majority shareholder in Protec Scientific, Inc. ("Protec"), a company formed in April 2020 by John Yorke for the purpose of designing, developing and marketing products that use spectral photonic emissions across a variety of applications. As of June 30, 2020, PSI had advanced $80,000 to Protec in furtherance of its agreement to acquire approximately 96% of Protec, with the Company's derivative share being approximately 48%, based on its PSI ownership. The remaining 52% derivative share is to be attributed to PSI's minority shareholders, based on their PSI ownership, and other investors.
Psoria-Shield, Inc [Member]
Ownership percentage					50.50%		50.50%
Additional paid-in capital					$ 80,000		$ 80,000
Gen 2 Funding, Inc [Member]
Ownership percentage					36.00%		36.00%
Proceeds from investment							$ 750,000
Illinois Limited Liability Company [Member]
Non-controlling interest, description							PSI had advanced $80,000 to Protec in furtherance of its agreement to acquire approximately 96% of Protec, with the Company's derivative share being approximately 48%, based on its PSI ownership. The remaining 52% derivative share is to be attributed to PSI's minority shareholders, based on their PSI ownership, and other investors. During the three months ended June 30, 2020, Protec recorded a loss of $79,926, of which $41,561 was allocated to the non-controlling interest. Subsequent to June 30, 2020, Protec received additional investments from non-affiliated investors.
Operating loss					$ 71,442		$ 161,604
Additional paid-in capital					35,007		35,007
Non-controlling interest					$ 79,186		$ 79,186
Stock Option [Member]
Antidilutive securities excluded from computation of earnings per share							13,765,238	15,687,738
Warrants [Member]
Antidilutive securities excluded from computation of earnings per share							67,634,049	66,832,049

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Schedule of Company's Consolidated Subsidiaries (Details)	9 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
State or other jurisdiction of incorporation or organization	Nevada
Psoria-Shield, Inc [Member]
Name of consolidated subsidiary or entity	Psoria-Shield Inc. ("PSI")
State or other jurisdiction of incorporation or organization	The State of Florida
Date of incorporation or formation	Jun. 17, 2009
Date of acquisition/disposition	Aug. 24, 2012
Attributable interest	51.00%
StealthCo, Inc. [Member]
Name of consolidated subsidiary or entity	StealthCo, Inc. ("StealthCo")
State or other jurisdiction of incorporation or organization	The State of Illinois
Date of incorporation or formation	Mar. 18, 2014
Attributable interest	100.00%
Psoria Development Company LLC. [Member]
Name of consolidated subsidiary or entity	Psoria Development Company LLC. ("PDC")
State or other jurisdiction of incorporation or organization	The State of Illinois
Date of incorporation or formation	Jan. 15, 2015
Date of acquisition/disposition	Nov. 15, 2018
Attributable interest	50.00%
NEO Phototherapy, LLC, [Member]
Name of consolidated subsidiary or entity	NEO Phototherapy LLC ("NEO")
State or other jurisdiction of incorporation or organization	The State of Illinois
Date of incorporation or formation	Dec. 31, 2018
Attributable interest	51.00%
Protec Scientific, Inc [Member]
Name of consolidated subsidiary or entity	Protec Scientific, Inc ("Protec")
State or other jurisdiction of incorporation or organization	The State of New York
Date of incorporation or formation	Apr. 30, 2020
Attributable interest		48.00%

Loans Payable from Officers a_2

Loans Payable from Officers and Shareholders (Details Narrative) - USD ($)	3 Months Ended
	Jun. 30, 2020	Sep. 30, 2019
Loans payable from officers and shareholders		$ 399,250
Due to officers and shareholders	$ 685,000
Debt instrument, interest rate, stated percentage	1.00%
Stock Price [Member]
Warrant measurement input	0.04
Volatility [Member]
Warrant measurement input	187
Risk-free Rates [Member]
Warrant measurement input	0.20
One of the Loan Holders [Member]
Debt instrument converted amount	$ 30,000
Debt instrument converted shares	575,000
Number of warrant to purchase of common stock	1,150,000
Warrants exercise price	$ 0.07
Warrant term	5 years
Officers and Shareholders [Member]
Fair value of warrants	$ 43,815
Loans payable to related parties	1,054,250
Calvin O Harrow [Member]
Loans payable to related parties	544,250
Roy Harsch [Member]
Loans payable to related parties	150,000
William Kingsford [Member]
Loans payable to related parties	131,000
Paul Jones [Member]
Loans payable to related parties	75,000
Douglas Samuelson [Member]
Loans payable to related parties	$ 30,000
22 Short-Term Unsecured Loans [Member]
Debt instrument, interest rate, stated percentage		8.00%

U.S. Small Business Administr_2

U.S. Small Business Administration Loan Payable (Details)	3 Months Ended
	Jun. 30, 2020USD ($)
U.s. Small Business Administration Loan Payable
Debt instrument, face amount	$ 37,166
Debt interest rate	1.00%
Debt maturity date	Apr. 23, 2022
Debt maturity description	Beginning in October 2020, PSI is required to make monthly interest payments and all principal and unpaid interest is due in April 2022.

Lease Liabilities (Details Narr

Lease Liabilities (Details Narrative) - USD ($)	1 Months Ended	3 Months Ended	9 Months Ended
	Feb. 28, 2019	Jun. 30, 2020	Jun. 30, 2020	Jun. 30, 2019	Oct. 02, 2019	Sep. 30, 2019
Leases [Abstract]
Lease term	24 months
Payment for lease liability	$ 1,800	$ 5,245	$ 15,584
Lease expiration date	2021-01
Right of use assets	$ 27,841	12,257	12,257
Lease, discount rate	4.00%
Lease liability		12,257	12,257		$ 27,841
Lease rent expense		5,400	16,200
Amortization of right of use asset		$ 5,245	$ 15,584

Shareholders' Equity (Details N

Shareholders' Equity (Details Narrative) - USD ($)	Jan. 02, 2020	Apr. 30, 2020	Mar. 31, 2020	Jun. 30, 2020	Jun. 30, 2020	Sep. 30, 2019	Jan. 02, 2018	Jun. 30, 2010
Number of vested shares				1,387,500
Common stock, shares authorized				200,000,000	200,000,000	200,000,000
Number of cancellation of stock options to purchase				3,360,000
Incremental fair value of warrants from modification				$ 22,680	$ 22,680
Number options to purchase of common stock					4,375,000
Options exercisable term					2 years 4 months 17 days
Unvested compensation				107,645	$ 107,645
Aggregate intrinsic value
Stock Option [Member]
Stock based compensation				66,306	$ 197,844
Minimum [Member]
Stock options exercise price					$ 0.14
Maximum [Member]
Stock options exercise price					$ 0.30
2010 Non-Qualified Stock Option Plan [Member]
Common stock, shares authorized							30,000,000	7,500,000
2010 Non-Qualified Stock Option Plan [Member] | Stock Option [Member]
Aggregate intrinsic value				$ 625	$ 625
Shares of stock options remaining available for issuance				16,234,762	16,234,762
Vest Monthly from April 2020 Through March 2021 [Member]
Number of vested shares		1,800,000
Vest Monthly from April 2020 Through March 2023 [Member]
Number of vested shares		11,250,000
Vest Over Time [Member]
Number of vested shares		13,050,000
Vest in April 2020 Through March 2021 [Member]
Number of cancellation of stock options to purchase					1,550,000
Stock options exercise price					$ 0.14
Board of Directors [Member]
Number of restricted shares issued during period, shares		19,910,000
Number of vested shares		6,860,000
Board of Directors [Member] | Stock Warrants [Member] | September 30, 2020 [Member]
Number of stock warrants approved for extension	66,000,000
Stock warrants extension, description	The Company's Board of Directors approved the extension of the Company's unexpired stock warrants as of December 31, 2019, by an additional one year period. This change affected approximately 66,000,000 warrant shares and approximately 20,000,000 warrant shares that were set to expire by the year ending September 30, 2020. The 20,000,000 warrant shares that were set to expire by September 30, 2020, had exercise prices ranging from $0.15 per share to $0.25 per share. The 66,000,000 warrant shares had exercise prices ranging from $0.12 per share to $0.40 per share.
Board of Directors [Member] | Stock Warrants [Member] | September 30, 2020 [Member]
Number of stock warrants approved for extension	20,000,000
Fair value of warrants					$ 507,265
Board of Directors [Member] | Minimum [Member] | Stock Warrants [Member] | September 30, 2020 [Member]
Exercise prices of stock warrants	$ 0.12
Board of Directors [Member] | Minimum [Member] | Stock Warrants [Member] | September 30, 2020 [Member]
Exercise prices of stock warrants	0.15
Board of Directors [Member] | Maximum [Member] | Stock Warrants [Member] | September 30, 2020 [Member]
Exercise prices of stock warrants	0.40
Board of Directors [Member] | Maximum [Member] | Stock Warrants [Member] | September 30, 2020 [Member]
Exercise prices of stock warrants	$ 0.25
CEO [Member]
Number of vested shares					500,000
Number of options to purchase common stock, shares					4,250,000
Stock option exercise price per share				$ 0.04	$ 0.04
Fair value of stock options					$ 127,500
Number of options re-priced during the period			1,200,000
Stock option repricing, description			Repricing of stock options to purchase 1,200,000 shares with an exercise price of $0.14 per share to $0.04 per share that had vested as of March 31, 2020,
CEO [Member] | Vest Monthly from April 2020 Through March 2021 [Member]
Number of options re-priced during the period			600,000
Stock option repricing, description			Repricing of stock options to purchase 600,000 shares with an exercise price of $0.14 per share to $0.04 per share that were set to vest monthly from April 2020 through March 2021.
CEO [Member] | Vest Monthly from April 2020 Through March 2023 [Member]
Number of vested shares					3,750,000
Employee [Member]
Stock option exercise price per share				$ 0.04	$ 0.04
Fair value of stock options					$ 4,688
Number options to purchase of common stock					125,000
Options exercisable term					5 years

Shareholders' Equity - Summary

Shareholders' Equity - Summary of Restricted Common Stock (Details)	9 Months Ended
	Jun. 30, 2020USD ($)$ / sharesshares
Equity [Abstract]
Number of Restricted Shares Non-vested, Beginning balance | shares
Number of Restricted Shares Non-vested, Granted | shares	19,910,000
Number of Restricted Shares Non-vested, Vested | shares	(8,247,500)
Number of Restricted Shares Non-vested, Forfeited | shares
Number of Restricted Shares Non-vested, Ending balance | shares	11,662,500
Fair Value Non-vested, Beginning balance | $
Fair Value Non-vested, Granted | $	597,300
Fair Value Non-vested, Vested | $	(247,425)
Fair Value Non-vested, Forfeited | $
Fair Value Non-vested, Ending balance | $	$ 349,875
Weighted Average Grant Date Fair Value Non-vested, Beginning balance | $ / shares
Weighted Average Grant Date Fair Value Non-vested, Granted | $ / shares	0.03
Weighted Average Grant Date Fair Value Non-vested, Vested | $ / shares	0.03
Weighted Average Grant Date Fair Value Non-vested, Forfeited | $ / shares
Weighted Average Grant Date Fair Value Non-vested, Ending balance | $ / shares	$ 0.03

Shareholders' Equity - Schedule

Shareholders' Equity - Schedule of Stock Option Activity (Details)	9 Months Ended
	Jun. 30, 2020$ / sharesshares
Number of Option Shares Outstanding, Number, Beginning Balance | shares	15,237,738
Number of Option Shares Outstanding, Granted | shares	4,375,000
Number of Option Shares Outstanding, Cancelled | shares	(4,910,000)
Number of Option Shares Outstanding, Exercised | shares
Number of Option Shares Outstanding, Expired | shares	(937,500)
Number of Option Shares Outstanding, Number, Ending Balance | shares	13,765,238
Number of Option Shares Outstanding, Vested and exercisable, Ending Balance | shares	9,877,738
Number of Option Shares Outstanding, Unvested, Ending Balance | shares	3,887,500
Weighted Average Exercise Price, Number, Beginning Balance	$ 0.27
Weighted Average Exercise Price, Granted	0.04
Weighted Average Exercise Price, Cancelled	0.14
Weighted Average Exercise Price, Exercised
Weighted Average Exercise Price, Expired	0.16
Weighted Average Exercise Price, Number, Ending Balance	0.24
Weighted Average Exercise Price, Vested and exercisable, Ending Balance	0.32
Weighted Average Exercise Price, Unvested, Ending Balance	0.04
Minimum [Member]
Weighted Average Exercise Price, Number, Beginning Balance	0.03
Weighted Average Exercise Price, Granted
Weighted Average Exercise Price, Cancelled	0.14
Weighted Average Exercise Price, Exercised
Weighted Average Exercise Price, Expired	0.11
Weighted Average Exercise Price, Number, Ending Balance	0.03
Weighted Average Exercise Price, Vested and exercisable, Ending Balance	.03
Weighted Average Exercise Price, Unvested, Ending Balance	0.04
Maximum [Member]
Weighted Average Exercise Price, Number, Beginning Balance	2
Weighted Average Exercise Price, Granted	0.04
Weighted Average Exercise Price, Cancelled	0.30
Weighted Average Exercise Price, Exercised
Weighted Average Exercise Price, Expired	0.25
Weighted Average Exercise Price, Number, Ending Balance	2
Weighted Average Exercise Price, Vested and exercisable, Ending Balance	2
Weighted Average Exercise Price, Unvested, Ending Balance	$ 0.14

Shareholders' Equity - Schedu_2

Shareholders' Equity - Schedule of Assumptions Used for Options Granted (Details)	9 Months Ended
	Jun. 30, 2020$ / shares
Exercise price	$ 0.04
Expected dividends
Expected life of options	2 years 6 months
Minimum [Member]
Expected volatility	157.60%
Risk free interest rate	0.26%
Maximum [Member]
Expected volatility	182.90%
Risk free interest rate	1.60%

Shareholders' Equity - Schedu_3

Shareholders' Equity - Schedule of Outstanding and Exercisable Options by Exercise Price Range (Details) - $ / shares	9 Months Ended
	Jun. 30, 2020	Sep. 30, 2019
Range of Exercise Prices, Lower Limit	$ 0.06
Range of Exercise Prices, Upper Limit	$ 2
Number of Options, Outstanding, Number	13,765,238	15,237,738
Number of Options, Outstanding, Weighted Average Remaining Contractual Term	3 years 18 days
Number of Options, Outstanding, Weighted Average Exercise Price	$ 0.24	$ 0.27
Number of Options, Exercisable, Number	9,877,738
Number of Options, Exercisable, Weighted Average Remaining Contractual Term	2 years 4 months 17 days
Number of Options, Exercisable, Weighted Average Exercise Price	$ 0.32
Exercise Price Range One [Member]
Range of Exercise Prices, Lower Limit	0.06
Range of Exercise Prices, Upper Limit	$ 0.39
Number of Options, Outstanding, Number	12,302,738
Number of Options, Outstanding, Weighted Average Remaining Contractual Term	3 years 4 months 2 days
Number of Options, Outstanding, Weighted Average Exercise Price	$ 0.09
Number of Options, Exercisable, Number	8,415,238
Number of Options, Exercisable, Weighted Average Remaining Contractual Term	2 years 8 months 12 days
Number of Options, Exercisable, Weighted Average Exercise Price	$ 0.12
Exercise Price Range Two [Member]
Range of Exercise Prices, Lower Limit	0.40
Range of Exercise Prices, Upper Limit	$ 0.99
Number of Options, Outstanding, Number	62,500
Number of Options, Outstanding, Weighted Average Remaining Contractual Term	1 year 9 months
Number of Options, Outstanding, Weighted Average Exercise Price	$ 0.40
Number of Options, Exercisable, Number	62,500
Number of Options, Exercisable, Weighted Average Remaining Contractual Term	1 year 9 months
Number of Options, Exercisable, Weighted Average Exercise Price	$ 0.40
Exercise Price Range Three [Member]
Range of Exercise Prices, Lower Limit	1
Range of Exercise Prices, Upper Limit	$ 1.99
Number of Options, Outstanding, Number	750,000
Number of Options, Outstanding, Weighted Average Remaining Contractual Term	6 months
Number of Options, Outstanding, Weighted Average Exercise Price	$ 1
Number of Options, Exercisable, Number	750,000
Number of Options, Exercisable, Weighted Average Remaining Contractual Term	6 months
Number of Options, Exercisable, Weighted Average Exercise Price	$ 1
Exercise Price Range Four [Member]
Range of Exercise Prices, Upper Limit	$ 2
Number of Options, Outstanding, Number	650,000
Number of Options, Outstanding, Weighted Average Remaining Contractual Term	6 months
Number of Options, Outstanding, Weighted Average Exercise Price	$ 2
Number of Options, Exercisable, Number	650,000
Number of Options, Exercisable, Weighted Average Remaining Contractual Term	6 months
Number of Options, Exercisable, Weighted Average Exercise Price	$ 2

Shareholders' Equity - Schedu_4

Shareholders' Equity - Schedule of Warrant Activity (Details) - Warrant [Member]	9 Months Ended
	Jun. 30, 2020$ / sharesshares
Number of Warrant Shares Outstanding, Number, Beginning Balance | shares	66,484,049
Number of Warrant Shares Outstanding, Granted | shares	1,150,000
Number of Warrant Shares Outstanding, Cancelled | shares
Number of Warrant Shares Outstanding, Exercised | shares
Number of Warrant Shares Outstanding, Expired | shares
Number of Warrant Shares Outstanding, Number, Ending Balance | shares	67,634,049
Number of Warrant Shares Outstanding, Vested and exercisable, Ending Balance | shares	67,634,049
Weighted Average Exercise Price, Number, Beginning Balance	$ 0.17
Weighted Average Exercise Price, Granted	0.07
Weighted Average Exercise Price, Cancelled
Weighted Average Exercise Price, Exercised
Weighted Average Exercise Price, Expired
Weighted Average Exercise Price, Number, Ending Balance	0.16
Weighted Average Exercise Price, Vested and exercisable, Ending Balance	0.16
Minimum [Member]
Weighted Average Exercise Price, Number, Beginning Balance	0.12
Weighted Average Exercise Price, Granted
Weighted Average Exercise Price, Cancelled
Weighted Average Exercise Price, Exercised
Weighted Average Exercise Price, Expired
Weighted Average Exercise Price, Number, Ending Balance	0.07
Weighted Average Exercise Price, Vested and exercisable, Ending Balance	0.07
Maximum [Member]
Weighted Average Exercise Price, Number, Beginning Balance	0.40
Weighted Average Exercise Price, Granted	0.07
Weighted Average Exercise Price, Cancelled
Weighted Average Exercise Price, Exercised
Weighted Average Exercise Price, Expired
Weighted Average Exercise Price, Number, Ending Balance	0.40
Weighted Average Exercise Price, Vested and exercisable, Ending Balance	$ 0.40

Shareholders' Equity - Schedu_5

Shareholders' Equity - Schedule of Outstanding and Exercisable Warrants by Exercise Price Range (Details) - $ / shares	9 Months Ended
	Jun. 30, 2020	Sep. 30, 2019
Range of Exercise Prices, Lower Limit	$ 0.06
Range of Exercise Prices, Upper Limit	$ 2
Number of Warrants, Outstanding, Number	13,765,238	15,237,738
Number of Warrants, Outstanding, Weighted Average Remaining Contractual Term	3 years 18 days
Number of Warrants, Outstanding, Weighted Average Exercise Price	$ 0.24	$ 0.27
Number of Warrants, Exercisable, Number	9,877,738
Number of Warrants, Exercisable, Weighted Average Remaining Contractual Term	2 years 4 months 17 days
Number of Warrants, Exercisable, Weighted Average Exercise Price	$ 0.32
Exercise Price Range One [Member]
Range of Exercise Prices, Lower Limit	0.06
Range of Exercise Prices, Upper Limit	$ 0.39
Number of Warrants, Outstanding, Number	12,302,738
Number of Warrants, Outstanding, Weighted Average Remaining Contractual Term	3 years 4 months 2 days
Number of Warrants, Outstanding, Weighted Average Exercise Price	$ 0.09
Number of Warrants, Exercisable, Number	8,415,238
Number of Warrants, Exercisable, Weighted Average Remaining Contractual Term	2 years 8 months 12 days
Number of Warrants, Exercisable, Weighted Average Exercise Price	$ 0.12
Exercise Price Range Two [Member]
Range of Exercise Prices, Lower Limit	0.40
Range of Exercise Prices, Upper Limit	$ 0.99
Number of Warrants, Outstanding, Number	62,500
Number of Warrants, Outstanding, Weighted Average Remaining Contractual Term	1 year 9 months
Number of Warrants, Outstanding, Weighted Average Exercise Price	$ 0.40
Number of Warrants, Exercisable, Number	62,500
Number of Warrants, Exercisable, Weighted Average Remaining Contractual Term	1 year 9 months
Number of Warrants, Exercisable, Weighted Average Exercise Price	$ 0.40
Warrant [Member]
Range of Exercise Prices, Lower Limit	0.12
Range of Exercise Prices, Upper Limit	$ 0.40
Number of Warrants, Outstanding, Number	67,634,049
Number of Warrants, Outstanding, Weighted Average Remaining Contractual Term	2 years 1 month 2 days
Number of Warrants, Outstanding, Weighted Average Exercise Price	$ 0.16
Number of Warrants, Exercisable, Number	67,634,049
Number of Warrants, Exercisable, Weighted Average Remaining Contractual Term	2 years 1 month 2 days
Number of Warrants, Exercisable, Weighted Average Exercise Price	$ 0.16
Warrant [Member] | Exercise Price Range One [Member]
Range of Exercise Prices, Lower Limit	0.12
Range of Exercise Prices, Upper Limit	$ 0.20
Number of Warrants, Outstanding, Number	60,429,384
Number of Warrants, Outstanding, Weighted Average Remaining Contractual Term	2 years 2 months 12 days
Number of Warrants, Outstanding, Weighted Average Exercise Price	$ 0.15
Number of Warrants, Exercisable, Number	60,429,384
Number of Warrants, Exercisable, Weighted Average Remaining Contractual Term	2 years 2 months 12 days
Number of Warrants, Exercisable, Weighted Average Exercise Price	$ 0.15
Warrant [Member] | Exercise Price Range Two [Member]
Range of Exercise Prices, Lower Limit	0.21
Range of Exercise Prices, Upper Limit	$ 0.40
Number of Warrants, Outstanding, Number	7,204,665
Number of Warrants, Outstanding, Weighted Average Remaining Contractual Term	1 year 1 month 16 days
Number of Warrants, Outstanding, Weighted Average Exercise Price	$ 0.26
Number of Warrants, Exercisable, Number	7,204,665
Number of Warrants, Exercisable, Weighted Average Remaining Contractual Term	1 year 1 month 16 days
Number of Warrants, Exercisable, Weighted Average Exercise Price	$ 0.26

Segment Reporting - Schedule of

Segment Reporting - Schedule of Assets of Reportable Segments (Details) - USD ($)	Jun. 30, 2020	Sep. 30, 2019	Feb. 28, 2019
Cash	$ 94,318	$ 53,147
Accounts receivable	5,000
Inventories	72,075
Prepaid expenses and other current assets	500	55,000
Total current assets	171,893	108,147
Right-of-use asset	12,257		$ 27,841
Total other assets	12,257	1,562
TOTAL ASSETS	184,150	$ 109,709
Corporate [Member]
Cash	39,770
Accounts receivable
Inventories
Prepaid expenses and other current assets	500
Total current assets	40,270
Right-of-use asset
Total other assets
TOTAL ASSETS	40,270
Medical Devices [Member]
Cash	51,402
Accounts receivable
Inventories	72,075
Prepaid expenses and other current assets
Total current assets	123,477
Right-of-use asset	12,257
Total other assets	12,257
TOTAL ASSETS	135,734
Authentication and Encryption [Member]
Cash	3,146
Accounts receivable	5,000
Inventories
Prepaid expenses and other current assets
Total current assets	8,146
Right-of-use asset
Total other assets
TOTAL ASSETS	$ 8,146

Segment Reporting - Schedule _2

Segment Reporting - Schedule of Operations of Reportable Segments (Details) - USD ($)	3 Months Ended		9 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Total Sales		$ 7,625	$ 5,000	$ 33,375
Cost of goods sold		4,575		20,025
Gross profit		3,050	5,000	13,350
Operating expenses	813,380	404,210	1,573,783	1,415,667
Loss from operations	(813,380)	(401,160)	(1,568,783)	(1,402,317)
Trade [Member]
Total Sales		3,108	5,000	19,508
Consulting Services [Member]
Total Sales		4,517		13,867
Corporate [Member]
Total Sales
Cost of goods sold
Gross profit
Operating expenses	620,650	175,784	861,611	716,900
Loss from operations	(620,650)	(175,784)	(861,611)	(716,900)
Corporate [Member] | Trade [Member]
Total Sales
Corporate [Member] | Consulting Services [Member]
Total Sales
Medical Devices [Member]
Total Sales
Cost of goods sold
Gross profit
Operating expenses	208,047	95,306	590,158	399,111
Loss from operations	(208,047)	(95,306)	(590,158)	(399,111)
Medical Devices [Member] | Trade [Member]
Total Sales
Medical Devices [Member] | Consulting Services [Member]
Total Sales
Authentication and Encryption [Member]
Total Sales		7,625	5,000	33,375
Cost of goods sold		4,575		20,057
Gross profit		3,050	5,000	13,350
Operating expenses	(15,317)	133,120	122,014	299,656
Loss from operations	15,317	(130,070)	(17,014)	(286,306)
Authentication and Encryption [Member] | Trade [Member]
Total Sales		3,108	5,000	19,508
Authentication and Encryption [Member] | Consulting Services [Member]
Total Sales		$ 4,517		$ 13,867

Legal Matters (Details Narrativ

Legal Matters (Details Narrative) - USD ($)	1 Months Ended	9 Months Ended
	Dec. 31, 2019	Jun. 30, 2020	Apr. 02, 2020
Payment to negotiated settlement	$ 89,302
Interest rate of negotiated settlement	4.00%
Wages	$ 25,600
Wages increase rate	2.00%
One of the Employees [Member]
Litigation settlement		$ 49,393
ex-CEO [Member]
Due to employees			$ 179,543
Loss contingency, receivable			$ 600,000

Commitments (Details Narrative)

Commitments (Details Narrative) - USD ($)	Jun. 29, 2020	Jun. 30, 2020	Jun. 30, 2020	Sep. 30, 2019
Lease expiration date			Feb. 28, 2024
Monthly lease payment			$ 11,000
Lease obligation remaining			631,587
Security deposit relating to the lease				$ 15,000
Operating lease obligation incurred		$ 334,557	$ 438,296
Operating lease, description			Commencing on October 1, 2016, the Company's wholly-owned subsidiary, StealthCo, entered into a non-cancellable lease agreement to lease its office facilities in Oak Ridge, Tennessee. The term of the lease is five years and expires September 30, 2021. On January 6, 2020, the Company entered into an agreement with the owners to terminate the agreement effective January 1, 2020. Under the agreement, the Company agreed to pay $11,000 and abandon certain Company property as documented in the agreement. During the nine months ended June 30, 2020, the $11,000 was paid by the Company.
Hanover Hoffman Estates LLC [Member]
Rent base	$ 672,878

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - Subsequent Event [Member]	Aug. 22, 2020USD ($)
Investments	$ 95,000
PSI [Member]
Derivative ownership	43.00%
Non-Affiliated Investors [Member]
Investments	$ 75,000